Home > Analytics > AJANTA PHARMA

AJANTA PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 532331     NSE : AJANTPHARM    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
Jul 24,2024
Price(EOD): ₹ 2,385.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 29,788.65 Cr
Value of ₹ 1 Lac invested in AJANTA PHARMA
on Jul 24,2019 (price: ₹ 594.20)

₹ 1 L

₹ 4.01 L

1W : 4.4% 1M : 2.3% 1Y : 66.7%
COMMUNITY POLL
for AJANTA PHARMA
Please provide your vote to see the results
AJANTA PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Industry Peers & Returns1W1M1Y
AJANTA PHARMA 4.4% 2.3% 66.7%
SUN PHARMACEUTICAL INDUSTRIES 1.6% 8.4% 48.1%
CIPLA -0.1% 0% 44.6%
DR REDDYS LABORATORIES 2.3% 12.4% 31.5%
ZYDUS LIFESCIENCES -0.5% 9.2% 89.1%
DIVIS LABORATORIES -0.8% 0.6% 24.2%
MANKIND PHARMA -1.6% -2.8% 10.8%
TORRENT PHARMACEUTICALS 3.1% 10.9% 63%
LUPIN -0% 15.9% 93%

FUNDAMENTAL ANALYSIS OF AJANTA PHARMA

 
Fundamentals Score
[ Q(TTM): Mar2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 AJANTPHARM is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF AJANTA PHARMA

 
Valuation Score
[As on : Jul 24,2024 ]

Ratio Consolidated
P/E
P/B
P/S
36.49
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 816.17 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

8.36
P/B Calculated based on Book Value of Rs 3,561.71 Cr
[Latest Year - Mar2024 - Consolidated Results ]

7.08
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,208.71 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 10% undervalued companies ! Discover More →

FAIR VALUE OF AJANTA PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
141%
41%
42%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF AJANTA PHARMA



AJANTA PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF AJANTA PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0
0
0
-
0
0
0
-
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF AJANTA PHARMA

Pledged Promoter Shares
12.33 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF AJANTA PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-4.62%
-11.38%
-4.42%
-3.48%
19.53%
86.33%
82.86%
65.82%
QtrlyTrend
0
Latest Qtr: Mar2024
Quarterly Result Analysis →


AJANTA PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 0.9% 6.3% 48.4%
S&P BSE ALLCAP -1.2% 3.2% 36.8%
S&P BSE LARGE MIDCAP -1.2% 3.1% 32.9%
S&P BSE 250 LARGEMIDCAP -1.2% 3.2% 33.5%
S&P BSE 500 -1.2% 3.1% 35.2%
NSE Indices1W1M1Y
NIFTY MIDCAP150 QUALITY 50 -0.9% 1.7% 39.5%
NIFTY 500 -1.2% 3.1% 35.9%
NIFTY500 MULTICAP 50:25:25 -1.3% 2.8% 43%
NIFTY LARGE MIDCAP 250 -1.3% 2.6% 41.7%
NIFTY MID SMALL400 -1.5% 2.3% 56.3%

You may also like the below Video Courses


FAQ about AJANTA PHARMA


Is AJANTA PHARMA good for long term investment?

As on Jul 24,2024, the Fundamentals of AJANTA PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AJANTA PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AJANTA PHARMA UnderValued or OverValued?

As on Jul 24,2024, AJANTA PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of AJANTA PHARMA ?

As on Jul 24,2024, the Intrinsic Value of AJANTA PHARMA is Rs. 1,679.01 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 988.14
Fair Value [Median EV / Sales Model] : Rs. 1,686.87
Fair Value [Median Price / Sales Model] : Rs. 1,679.01
Estimated Median Fair Value of AJANTA PHARMA : Rs. 1,679.01

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is AJANTA PHARMA trading at a Premium or Discount?

As on Jul 24,2024, AJANTA PHARMA is trading at a Premium of 42% based on the estimates of Median Intrinsic Value!